References
- Ramsay AG. JCI 2008.
- Bertilaccio et al. Blood 2010.
- Giordano-Attianese. Blood 2010.
References
- Uchida J, et al. J Exp Med 199, 1659 (Jun 21, 2004).
- Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. Clin Cancer Res 13, 5784 (Oct 1, 2007).
- Borge M, et al. Haematologica 2015 Jan 23. [Epub ahead of print].
- Bojarczuk K, et al. Leukemia 28, 1163 (May, 2014).
References
- O';Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165–70.
- Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326–31.
- Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038–43.
Reference
- Pascutti, et al. Blood 2013.
References
- Puiggros A, Blanco G, and Espinet B. Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int 2014; 2014:435983.
- Dohner H. et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997; 89:2516–22.
- Jaksic O. et al. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 2004; 103:1968–9.
References
- Dickinson JD, et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006; 47:231–44.
- Bertilaccio MT, et al. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia 2013;27:534–40.
- Collins RJ, et al. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br J Haematol 1989;71:343–50.
References
- Petlickovski A, et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005;105:4820–7.
- Longo PG, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111:846–55.
- Hofbauer SW, et al. Modifying Akt signaling in B-cell chronic lymphocytic leukemia cells. Cancer Res. 2010;70:7336–44.
- de Frias M, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2009;94:1698–707.
- Zhuang J, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica. 2010;95:110–8.
- Ding W, et al. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. Br J Haematol 2014;164:146–50.
- Davies BR, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873–87.
References
- Pflug, et al.
References
- van Oers M, et al. Ofatumumab (OFA) Maintenance prolongs PFS in Relapsed CLL: PROLONG Study Interim Analysis Results. Blood (ASH Annual Meeting Abstracts), 2014;124: Abstract 21.
References
- Mulligan SP, et al. Cladribine prolongs PFS and time to second treatment compared to fludarabine and high-dose chlorambucil in CLL. Leuk Lymphoma 2014.
- Mulligan SP, et al. A randomised dose de-escalation study of FCR in the elderly. iwCLL Abstract, 2015.
References
- Mulligan SP, et al. A randomised dose de-escalation study of oral fludarabine, +/− oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukemia aged 65 years. iwCLL Abstract 2015.
References
- Kaucka M, et al. The planar cell polarity pathway drives pathogenesis of chronic lymphocytic leukemia by the regulation of B-lymphocyte migration. Cancer research 73, 1491 (Mar 1, 2013).
- Janovska P, Poppova L, et al. Autocrine signalling by Wnt-5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. Clinical Cancer Research, (in revision).
References
- Mackus W. J. et al., Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 19, 427–434 (2005).
- Smit L. A. et al., Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109, 1660–1668 (2007).
References
- Chanan-Khan A, et al. ASCO 2015.
Reference
- Chanan-Khan A, et al. ASCO 2015.
References
- Byrd JC, et al. NEJM. 2014;371:213–223.
- Chanan-Khan A, et al. ASCO 2015.